• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
    • Emerging Biopharma
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
    • Emerging Biopharma
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

Yervoy

Biotech

Jounce gets trounced as phase 2 data disappoint once again

Jounce is reevaluating a top monoclonal antibody program after it failed to adequately reduce tumor size in combination with another lead asset.
Max Bayer Aug 31, 2022 7:30am

BMS melanoma, genitourinary commercial lead heads to miR

Aug 13, 2021 9:45am

BMS' LAG-3 drug boosts Opdivo in staving off melanoma

May 19, 2021 5:00pm

Idera's TLR9 drug flunks melanoma phase 3, tanking stock

Mar 19, 2021 8:45am

Xilio raises $95M to take twists on Yervoy and IL-2 into clinic 

Feb 24, 2021 8:00am

Jounce sinks as it ditches phase 2 Yervoy combo trial

Nov 3, 2020 9:55am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy